title: Indirect parameters of pancreatic function in cystic fibrosis (CF) during a controlled double-blind trial of pancreatic supplementation.
abstract: During two treatment periods (4 weeks each), serum immunoreactive trypsin (IRT), immunoreactive human lipase in stool (IRL), and chymotrypsin (CT) activity in stool were determined in 16 cystic fibrosis patients and compared with fecal fat excretion (72-h sampling). Fecal fat estimation revealed mild to severe steatorrhea in all 16 patients (X = 13.7 +/- 9.0 g/24 h) in at least one study period. Stool fat excretion was highest in underweight adolescents and adults. Comparison of IRT and IRL with stool fat values showed no significant statistical correlation. IRT values revealed an inverse exponential correlation with age, with a steep decline at the age of 5 years. CT levels were very high in 14 of our 16 patients during supplementation therapy, whereas 2 patients showed subnormal CT values. We conclude that since indirect parameters of pancreatic function do not correlate with stool fat excretion, stool fat remains the best indirect parameter for the assessment of pancreatic insufficiency in cystic fibrosis. Leaving pancreatic enzyme supplementation in cystic fibrosis patients on the basis of normal serum trypsin or fecal lipase values does not appear to be adequate.
authors.affiliation: Pediatric Gastroenterology Group, University Children's Clinic, Tübingen, Germany.
authors.forename: S
authors.initials: S
authors.lastname: Regele
authors.forename: J
authors.initials: J
authors.lastname: Henker
authors.forename: R
authors.initials: R
authors.lastname: Münch
authors.forename: Y
authors.initials: Y
authors.lastname: Barbier
authors.forename: M
authors.initials: M
authors.lastname: Stern
mesh_terms: D000293:Adolescent; D000328:Adult; D002648:Child; D002675:Child, Preschool; D002918:Chymotrypsin / Q000032:analysis; D003550:Cystic Fibrosis / Q000150:complications / Q000503:physiopathology*; D004311:Double-Blind Method; D010188:Exocrine Pancreatic Insufficiency / Q000150:complications / Q000188:drug therapy* / Q000503:physiopathology; D005243:Feces / Q000737:chemistry; D005260:Female; D005765:Gastrointestinal Agents / Q000627:therapeutic use*; D006801:Humans; D008049:Lipase / Q000032:analysis; D008055:Lipids / Q000032:analysis; D008297:Male; D010179:Pancreas / Q000503:physiopathology*; D010194:Pancreatin / Q000627:therapeutic use*; D014357:Trypsin / Q000097:blood
chemical_list: D005765:Gastrointestinal Agents; D008055:Lipids; D010194:Pancreatin; D008049:Lipase; D002918:Chymotrypsin; D014357:Trypsin